Considering that IL-1β is a characteristic of the inflammatory response induced by GBS, Ayash and collaborators demonstrated in vivo that blocking IL-1β in GBS-induced chorioamnionitis at the end of gestation can result in a reduction in GBS-induced placental and fetal inflammation without aggravating the infection, indicating a possible prevention of neurobehavioral complications related to this cytokine [170]. The gene discussed is IL1B; the disease is chorioamnionitis.